DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Healthcare
Author Program NEWCreate Narrative
EMBC logo

Embecta Corp. Stock Price

NasdaqGS:EMBC Community·US$279.6m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 15 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

EMBC Share Price Performance

US$4.94
-10.07 (-67.09%)
​
US$4.00
Fair Value
US$4.94
-10.07 (-67.09%)
23.5% overvalued intrinsic discount
US$4.00
Fair Value
Price US$4.94
AnalystConsensusTarget US$4.00
AnalystLowTarget US$3.00
AnalystHighTarget US$5.00
Tue, 14 Jul 26
Fair ValueUS$4.00
Share Pricen/a

EMBC Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$4 23.5% overvalued intrinsic discount

GLP-1 Partnerships Will Expand Global Healthcare Reach

1users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$3 64.7% overvalued intrinsic discount

Global Healthcare Margins Will Erode Under Tightening Reimbursement Pressures

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$5 1.2% undervalued intrinsic discount

Aging And Digital Trends Will Advance Insulin Delivery Solutions

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
EMBC logo
Embecta
23.5% overvalued intrinsic discount

GLP-1 Partnerships Will Expand Global Healthcare Reach

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 14 Jul
Read Narrative
EMBC logo
Embecta
64.7% overvalued intrinsic discount

Global Healthcare Margins Will Erode Under Tightening Reimbursement Pressures

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 29 Jun
Read Narrative
EMBC logo
Embecta
1.2% undervalued intrinsic discount

Aging And Digital Trends Will Advance Insulin Delivery Solutions

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 15 Jun
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystConsensusTarget
EMBC logo

EMBC: Wound Care Expansion Will Support Future Upside Despite Legal And Medtech Headwinds

Fair Value: US$4 23.5% overvalued intrinsic discount
10 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
EMBC logo

EMBC: Medtech Repricing And Index Removals Will Pressure Future Returns

Fair Value: US$3 64.7% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
EMBC logo

EMBC: Medtech Reset And Buybacks May Support Future Rebound Potential

Fair Value: US$5 1.2% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Undervalued with acceptable track record.

3 Risks
3 Rewards
View Full Analysis

Embecta Corp. Key Details

US$1.0b

Revenue

US$423.6m

Cost of Revenue

US$595.1m

Gross Profit

US$507.6m

Other Expenses

US$87.5m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
1.54
58.42%
8.59%
-237.5%
View Full Analysis

About EMBC

Founded
1924
Employees
1850
CEO
Devdatt Kurdikar
WebsiteView website
www.embecta.com

Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company’s products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient’s diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

Recent EMBC News & Updates

Seeking Alpha • Aug 25

The Bottom Fishing Club - Embecta: Excellent Turnaround Prospect In Defensive Medical Products

Summary Embecta offers a compelling deep value opportunity, trading at a P/E below 3x and free cash flow yield above 50%. Despite slightly declining sales and excessive debt, EMBC's high gross margins (59.6%) and market leadership position support a bullish 12-month target of $8-10 per share. Technical momentum has turned positive, with insider buying and extended short interest setting up the potential for a sharp rebound if fundamentals stabilize. I rate EMBC a Buy under $7, with Strong Buy territory pegged below $4, citing takeover potential and defensive sector appeal amid market rotation. Read the full article on Seeking Alpha

Recent updates

No updates

Embecta Corp. Competitors

QDEL logo

QuidelOrtho

Symbol: NasdaqGS:QDEL
Market cap: US$833.2m
SIBN logo

SI-BONE

Symbol: NasdaqGM:SIBN
Market cap: US$820.2m
AVR logo

Anteris Technologies Global

Symbol: NasdaqGM:AVR
Market cap: US$808.9m
AHCO logo

AdaptHealth

Symbol: NasdaqCM:AHCO
Market cap: US$808.5m
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide